Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-11-15-Speech-2-182"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20051115.25.2-182"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, ladies and gentlemen, in France, almost 10% of cancers developed by workers each year are related to their exposure to chemicals at their place of work. In the absence of useable data on these chemicals, however, only a tiny proportion of these cancers are recognised as occupational diseases and dealt with as such. More generally, we are seeing an exponential increase in the incidence of cancer affecting the whole of the population, particularly children, which has led many scientists to conclude that these cancers are directly related to chemical production. That demonstrates the importance attached to the entry into force of a system of assessment, authorisation and substitution of chemicals.
All of us here are keen to guarantee the competitiveness of the European chemical industry and thus to protect jobs. For my part, I have always advocated the idea that the system adopted should be technically and economically sustainable for business and, to this end, promote consortiums. However, we do not want a REACH on the cheap.
In order for REACH to make it truly possible to eliminate harmful substances from the European market, there are two conditions. First, the determination of the nature and the potential risks of substances is directly dependent on the quality of the information supplied during registration. No amendment must result in the registration aspect being rendered powerless and, in this regard, derogations from the obligation to provide data must be exceptional and strictly limited, including for substances produced in small quantities. The burden of proof must lie with the companies.
Secondly, we must give all the citizens of Europe, and all workers, the assurance that harmful substances will be removed from circulation and replaced with safe products. The implementation of a substitution requirement, and not just a recommendation, is non-negotiable. Thus, a harmful substance must not be granted authorisation for placing on the market if an alternative product exists.
In my view, it is in the light of these requirements that we must consider our vote at first reading. The socialists in the Committee on the Internal Market and Consumer Protection for whom I am the shadow rapporteur were satisfied with a compromise fairly similar to the one we have before us today. On the other hand, other members of our group, particularly the French socialists, would have liked a more ambitious compromise.
To conclude, I would like to thank our rapporteur, Mr Sacconi, for the hard work he has put in."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples